CURE/Digestive Diseases Research Center, Center for Neurobiology of Stress, Department of Medicine, Digestive Diseases Division at the University of California Los Angeles, and Veterans Affairs Greater Los Angeles Health Care System, CA 90073, USA.
Physiol Behav. 2010 Dec 2;101(5):614-22. doi: 10.1016/j.physbeh.2010.09.009. Epub 2010 Sep 17.
We recently reported that the oligosomatostatin receptor agonist, ODT8-SST increases food intake in rats via the somatostatin 2 receptor (sst(2)). We characterized ingestive behavior following intracerebroventricular (icv) injection of a selective sst(2) agonist in freely fed mice during the light phase. The sst(2) agonist (0.01, 0.03, 0.1, 0.3 or 1μg/mouse) injected icv under short inhalation anesthesia dose-dependently increased cumulative light phase food intake over 4h compared to vehicle with a 3.1-times increase at 1μg/mouse (p<0.05). Likewise, the sst(2,3,5) agonist octreotide (0.3 or 1μg/mouse) dose-dependently increased 4-h food intake, whereas selective sst(1) or sst(4) agonists at 1μg/mouse did not. In vehicle-treated mice, high fat diet increased caloric intake/4h by 2.8-times compared to regular diet (p<0.05) and values were further increased 1.4-times/4h by the sst(2) agonist. Automated continuous assessment of food intake established a 6.6-times higher food intake during the dark phase due to increased number of meals, meal size, meal duration and rate of ingestion compared to non-treated mice during the light phase. During the first 4h post icv sst(2) agonist injection, mice had a 57% increase in number of meals with a 60% higher rate of ingestion, and a 61% reduction in inter-meal intervals, whereas meal sizes were not altered compared to vehicle. These data indicate that the activation of brain sst(2) receptors potently stimulates the light phase ingestive behavior under basal or high fat diet-stimulated conditions in mice. The shortened inter-meal interval suggests an inhibitory effect of the sst(2) agonist on "satiety", whereas "satiation" is not altered as indicated by normal meal size.
我们最近报道称,奥曲肽受体激动剂 ODT8-SST 通过生长抑素 2 受体(sst(2))增加大鼠的食物摄入。我们描述了在光照期内自由进食的小鼠中,侧脑室(icv)注射选择性 sst(2)激动剂后摄食行为的特征。sst(2)激动剂(0.01、0.03、0.1、0.3 或 1μg/只)在短吸入麻醉下 icv 注射,与载体相比,4 小时内累积光照期食物摄入量呈剂量依赖性增加,1μg/只时增加 3.1 倍(p<0.05)。同样,sst(2,3,5)激动剂奥曲肽(0.3 或 1μg/只)呈剂量依赖性增加 4 小时食物摄入量,而 1μg/只的选择性 sst(1)或 sst(4)激动剂则没有。在载体处理的小鼠中,高脂肪饮食使 4 小时内的热量摄入增加 2.8 倍(p<0.05),而 sst(2)激动剂则使该值进一步增加 1.4 倍/4 小时。食物摄入量的自动连续评估建立了一个在黑暗期,由于进食次数、餐大小、餐持续时间和进食速度的增加,相对于光照期未经处理的小鼠,食物摄入量增加了 6.6 倍。在侧脑室注射 sst(2)激动剂后的头 4 小时内,与载体相比,小鼠的进食次数增加了 57%,进食速度提高了 60%,而两次进食之间的间隔时间减少了 61%,而每餐的大小则没有改变。这些数据表明,在基础或高脂肪饮食刺激条件下,大脑 sst(2)受体的激活在小鼠中有力地刺激了光照期的摄食行为。较短的两次进食之间的间隔时间表明 sst(2)激动剂对“饱腹感”有抑制作用,而正常的餐大小表明“饱食感”没有改变。